OTC : CSPCY
$0.05 (1.24%)
| Source | Headline |
|---|---|
|
AstraZeneca signs CSPC China deal for experimental kidney disease drugs
AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday. reuters.com - 2026-07-02 06:16:16 |